| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| STAT3 Transcription Factor | 12 | 2023 | 1132 | 1.540 |
Why?
|
| Interleukin-6 | 5 | 2011 | 1032 | 0.870 |
Why?
|
| GPI-Linked Proteins | 6 | 2013 | 233 | 0.860 |
Why?
|
| Janus Kinases | 2 | 2020 | 175 | 0.710 |
Why?
|
| Fibrosis | 2 | 2020 | 715 | 0.680 |
Why?
|
| Naphthols | 2 | 2017 | 25 | 0.670 |
Why?
|
| Pancreatic Neoplasms | 13 | 2013 | 5257 | 0.510 |
Why?
|
| Dendritic Cells | 5 | 2010 | 1104 | 0.490 |
Why?
|
| Cell Proliferation | 9 | 2017 | 7232 | 0.440 |
Why?
|
| src Homology Domains | 2 | 2023 | 133 | 0.390 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2011 | 65 | 0.370 |
Why?
|
| Inflammation | 1 | 2020 | 2492 | 0.350 |
Why?
|
| Sulfonamides | 2 | 2017 | 1942 | 0.350 |
Why?
|
| Cyclin E | 2 | 2008 | 284 | 0.330 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2020 | 1570 | 0.320 |
Why?
|
| NF-kappa B | 3 | 2013 | 1555 | 0.310 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2008 | 252 | 0.280 |
Why?
|
| Membrane Glycoproteins | 2 | 2008 | 1091 | 0.280 |
Why?
|
| Antineoplastic Agents | 6 | 2020 | 14638 | 0.270 |
Why?
|
| Cell Line, Tumor | 16 | 2021 | 14876 | 0.270 |
Why?
|
| Cyclophilin A | 1 | 2005 | 23 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2011 | 1544 | 0.240 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 1704 | 0.240 |
Why?
|
| Lipopolysaccharide Receptors | 4 | 2010 | 90 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 2051 | 0.230 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2007 | 770 | 0.230 |
Why?
|
| Cation Transport Proteins | 3 | 2010 | 168 | 0.220 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 344 | 0.220 |
Why?
|
| CD40 Ligand | 2 | 2017 | 130 | 0.220 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2007 | 1362 | 0.200 |
Why?
|
| Aspergillosis | 1 | 2024 | 248 | 0.200 |
Why?
|
| Cytokines | 6 | 2024 | 2803 | 0.190 |
Why?
|
| Genetics, Population | 4 | 2003 | 258 | 0.190 |
Why?
|
| Cell Survival | 5 | 2017 | 3058 | 0.180 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 4148 | 0.180 |
Why?
|
| Mucormycosis | 1 | 2022 | 118 | 0.180 |
Why?
|
| Signal Transduction | 4 | 2017 | 12041 | 0.180 |
Why?
|
| Interleukin-2 | 2 | 2024 | 889 | 0.180 |
Why?
|
| Apoptosis | 4 | 2016 | 7755 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 5595 | 0.170 |
Why?
|
| Enzyme Activation | 4 | 2017 | 1801 | 0.170 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 492 | 0.170 |
Why?
|
| S Phase | 2 | 2011 | 289 | 0.160 |
Why?
|
| Monocytes | 3 | 2007 | 784 | 0.160 |
Why?
|
| Prodrugs | 1 | 2020 | 226 | 0.150 |
Why?
|
| Tyrphostins | 2 | 2008 | 110 | 0.150 |
Why?
|
| Animals | 19 | 2024 | 61346 | 0.150 |
Why?
|
| Mice, Nude | 6 | 2016 | 4332 | 0.140 |
Why?
|
| Janus Kinase 2 | 2 | 2015 | 755 | 0.140 |
Why?
|
| CD40 Antigens | 1 | 2017 | 107 | 0.140 |
Why?
|
| Phosphorylation | 4 | 2020 | 4907 | 0.140 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 694 | 0.140 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 453 | 0.140 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2016 | 30 | 0.130 |
Why?
|
| Dioxolanes | 1 | 2015 | 51 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 653 | 0.130 |
Why?
|
| Blotting, Western | 5 | 2021 | 3568 | 0.130 |
Why?
|
| RNA, Small Interfering | 3 | 2015 | 2192 | 0.130 |
Why?
|
| Neoplasms | 3 | 2020 | 15931 | 0.130 |
Why?
|
| Colitis, Ulcerative | 1 | 2018 | 260 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 704 | 0.130 |
Why?
|
| Platelet Activation | 1 | 2015 | 100 | 0.130 |
Why?
|
| Mice | 14 | 2024 | 35412 | 0.120 |
Why?
|
| Melanoma, Experimental | 1 | 2017 | 381 | 0.120 |
Why?
|
| Platelet Aggregation | 1 | 2015 | 180 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2017 | 3924 | 0.120 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 1089 | 0.120 |
Why?
|
| Crohn Disease | 1 | 2018 | 332 | 0.120 |
Why?
|
| Cardiotoxicity | 1 | 2016 | 152 | 0.120 |
Why?
|
| MicroRNAs | 3 | 2013 | 2882 | 0.120 |
Why?
|
| Synovial Membrane | 1 | 2014 | 46 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 561 | 0.120 |
Why?
|
| Receptors, KIR | 1 | 2014 | 64 | 0.110 |
Why?
|
| Morpholines | 2 | 2016 | 296 | 0.110 |
Why?
|
| Humans | 36 | 2024 | 270601 | 0.110 |
Why?
|
| DNA | 4 | 2023 | 3041 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 1656 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2015 | 9047 | 0.110 |
Why?
|
| Radiation Tolerance | 1 | 2016 | 639 | 0.100 |
Why?
|
| Collagen | 1 | 2015 | 723 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2017 | 472 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 2 | 2013 | 1072 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2013 | 2454 | 0.100 |
Why?
|
| Luciferases, Renilla | 1 | 2011 | 10 | 0.100 |
Why?
|
| Cyclin A | 1 | 2011 | 49 | 0.100 |
Why?
|
| DNA Primers | 2 | 2011 | 1489 | 0.100 |
Why?
|
| Coumarins | 1 | 2011 | 38 | 0.100 |
Why?
|
| Chromones | 1 | 2011 | 121 | 0.100 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 444 | 0.100 |
Why?
|
| Gene Silencing | 3 | 2009 | 825 | 0.100 |
Why?
|
| Tandem Repeat Sequences | 2 | 2002 | 203 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 1107 | 0.090 |
Why?
|
| Lymphocyte Activation | 3 | 2020 | 1719 | 0.090 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 1003 | 0.090 |
Why?
|
| Alleles | 4 | 2014 | 2597 | 0.090 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 3943 | 0.090 |
Why?
|
| Microsatellite Repeats | 2 | 2003 | 627 | 0.090 |
Why?
|
| Caspase 3 | 1 | 2011 | 460 | 0.090 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 247 | 0.090 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2011 | 288 | 0.090 |
Why?
|
| RNA Interference | 2 | 2011 | 1381 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2395 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 1127 | 0.080 |
Why?
|
| Genes, Reporter | 1 | 2011 | 813 | 0.080 |
Why?
|
| Norwalk virus | 1 | 2010 | 173 | 0.080 |
Why?
|
| Protein Transport | 1 | 2011 | 738 | 0.080 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2010 | 196 | 0.080 |
Why?
|
| Mammary Glands, Animal | 1 | 2013 | 618 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2014 | 494 | 0.080 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2017 | 1162 | 0.080 |
Why?
|
| Cell Differentiation | 4 | 2007 | 4104 | 0.080 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 965 | 0.080 |
Why?
|
| Doxorubicin | 1 | 2016 | 3145 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 1557 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 622 | 0.080 |
Why?
|
| India | 5 | 2014 | 311 | 0.080 |
Why?
|
| Cholesterol Esters | 1 | 2007 | 19 | 0.080 |
Why?
|
| Foam Cells | 1 | 2007 | 27 | 0.070 |
Why?
|
| Immunotherapy, Active | 1 | 2008 | 48 | 0.070 |
Why?
|
| Base Sequence | 2 | 2011 | 5405 | 0.070 |
Why?
|
| Neuropilin-1 | 1 | 2007 | 40 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 2386 | 0.070 |
Why?
|
| Thymosin | 1 | 2007 | 28 | 0.070 |
Why?
|
| Gene Expression | 2 | 2014 | 3606 | 0.070 |
Why?
|
| Pentoxifylline | 1 | 2007 | 38 | 0.070 |
Why?
|
| Culture Media, Conditioned | 1 | 2007 | 254 | 0.070 |
Why?
|
| Macrophages | 2 | 2010 | 1333 | 0.070 |
Why?
|
| Cyclophilins | 1 | 2006 | 31 | 0.070 |
Why?
|
| Basigin | 1 | 2006 | 22 | 0.070 |
Why?
|
| Stem Cells | 1 | 2013 | 1211 | 0.070 |
Why?
|
| Antigen Presentation | 1 | 2007 | 286 | 0.070 |
Why?
|
| Th2 Cells | 1 | 2007 | 245 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2017 | 2189 | 0.070 |
Why?
|
| Curcumin | 1 | 2006 | 119 | 0.070 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 317 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 2986 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2006 | 300 | 0.060 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 1385 | 0.060 |
Why?
|
| Antigens, CD34 | 1 | 2007 | 639 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 538 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2006 | 366 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 4964 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2007 | 556 | 0.060 |
Why?
|
| Coronary Vessels | 1 | 2008 | 606 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 863 | 0.060 |
Why?
|
| Lentivirus | 1 | 2024 | 165 | 0.050 |
Why?
|
| Cell Line | 2 | 2015 | 5313 | 0.050 |
Why?
|
| Aspergillus fumigatus | 1 | 2024 | 136 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2022 | 1095 | 0.050 |
Why?
|
| Aspergillus | 1 | 2024 | 150 | 0.050 |
Why?
|
| Cell Cycle | 1 | 2008 | 2134 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2022 | 7311 | 0.050 |
Why?
|
| Melanoma | 1 | 2020 | 5597 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2008 | 1031 | 0.050 |
Why?
|
| Liver Neoplasms | 2 | 2017 | 4837 | 0.050 |
Why?
|
| Tyrosine | 1 | 2023 | 503 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 5417 | 0.050 |
Why?
|
| Alkylation | 1 | 2021 | 32 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2021 | 94 | 0.050 |
Why?
|
| Surface Plasmon Resonance | 1 | 2021 | 97 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 1944 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2024 | 709 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 1580 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 7050 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 4966 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 2020 | 1169 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2021 | 162 | 0.040 |
Why?
|
| Pregnancy | 1 | 2013 | 7914 | 0.040 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2020 | 195 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 975 | 0.040 |
Why?
|
| Ligands | 1 | 2021 | 1007 | 0.040 |
Why?
|
| Carcinoma | 1 | 2009 | 2610 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 2017 | 57 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2021 | 1469 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2024 | 882 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 5581 | 0.040 |
Why?
|
| Up-Regulation | 3 | 2010 | 2413 | 0.040 |
Why?
|
| Superoxides | 2 | 2008 | 215 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 3582 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2017 | 5692 | 0.040 |
Why?
|
| Cachexia | 1 | 2018 | 154 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2017 | 184 | 0.030 |
Why?
|
| Binding Sites | 1 | 2021 | 2249 | 0.030 |
Why?
|
| Gene Frequency | 2 | 2014 | 1246 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 4 | 2003 | 3464 | 0.030 |
Why?
|
| Probability | 2 | 2007 | 886 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2020 | 765 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 395 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2017 | 423 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2003 | 2157 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 2343 | 0.030 |
Why?
|
| Genotype | 2 | 2014 | 4246 | 0.030 |
Why?
|
| Octamer Transcription Factor-2 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Pre-B-Cell Leukemia Transcription Factor 1 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Valosin Containing Protein | 1 | 2013 | 14 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 2 | 2008 | 884 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2017 | 677 | 0.030 |
Why?
|
| Autocrine Communication | 1 | 2013 | 88 | 0.030 |
Why?
|
| Caseins | 1 | 2013 | 75 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2014 | 494 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 2013 | 275 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 12038 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2017 | 1490 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 1008 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2014 | 843 | 0.020 |
Why?
|
| Lactation | 1 | 2013 | 234 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 7643 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2013 | 428 | 0.020 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2010 | 21 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2016 | 696 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2009 | 5759 | 0.020 |
Why?
|
| Viral Tropism | 1 | 2010 | 41 | 0.020 |
Why?
|
| Fucosyltransferases | 1 | 2010 | 78 | 0.020 |
Why?
|
| Asthma | 1 | 2018 | 893 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2010 | 113 | 0.020 |
Why?
|
| Progesterone | 1 | 2013 | 711 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2010 | 116 | 0.020 |
Why?
|
| ABO Blood-Group System | 1 | 2010 | 125 | 0.020 |
Why?
|
| Female | 6 | 2020 | 148790 | 0.020 |
Why?
|
| Targeted Gene Repair | 1 | 2009 | 5 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2008 | 5658 | 0.020 |
Why?
|
| Untranslated Regions | 1 | 2009 | 15 | 0.020 |
Why?
|
| Biopsy | 1 | 2017 | 3491 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 7919 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 676 | 0.020 |
Why?
|
| Estrogens | 1 | 2013 | 806 | 0.020 |
Why?
|
| Species Specificity | 1 | 2010 | 783 | 0.020 |
Why?
|
| Interferon Type I | 1 | 2010 | 282 | 0.020 |
Why?
|
| Anions | 1 | 2008 | 34 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2009 | 116 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2010 | 495 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 2419 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 5157 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 3416 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6257 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 1696 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2010 | 591 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2007 | 97 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2008 | 356 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2007 | 6344 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 2033 | 0.020 |
Why?
|
| Caliciviridae Infections | 1 | 2010 | 323 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2008 | 277 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 9460 | 0.020 |
Why?
|
| RNA, Untranslated | 1 | 2009 | 242 | 0.020 |
Why?
|
| Virion | 1 | 2008 | 185 | 0.020 |
Why?
|
| Rats | 1 | 2016 | 6397 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 3472 | 0.020 |
Why?
|
| Male | 6 | 2017 | 128395 | 0.020 |
Why?
|
| Virus Replication | 1 | 2010 | 762 | 0.020 |
Why?
|
| Biological Transport | 1 | 2007 | 630 | 0.020 |
Why?
|
| Disease Progression | 2 | 2008 | 6867 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 3205 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 5144 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 469 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2006 | 311 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 2112 | 0.010 |
Why?
|
| Antioxidants | 1 | 2007 | 519 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2014 | 6234 | 0.010 |
Why?
|
| Brain | 1 | 2017 | 4201 | 0.010 |
Why?
|
| Lung | 1 | 2015 | 3284 | 0.010 |
Why?
|
| Swine | 1 | 2008 | 1514 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2009 | 2087 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 2618 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2017 | 3557 | 0.010 |
Why?
|
| Oxygen | 1 | 2008 | 786 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2007 | 2316 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2006 | 805 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2007 | 669 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 5318 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 2478 | 0.010 |
Why?
|
| Mutation | 1 | 2023 | 15905 | 0.010 |
Why?
|
| Transfection | 1 | 2008 | 3109 | 0.010 |
Why?
|
| Forensic Medicine | 1 | 2002 | 18 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 1624 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 1381 | 0.010 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2013 | 1830 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 4105 | 0.010 |
Why?
|
| Software | 1 | 2009 | 1357 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2009 | 1715 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2007 | 3040 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 7912 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 4992 | 0.010 |
Why?
|
| Cell Movement | 1 | 2008 | 2468 | 0.010 |
Why?
|
| Aged | 2 | 2017 | 73534 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 1307 | 0.010 |
Why?
|
| Atherosclerosis | 1 | 2007 | 908 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 3186 | 0.010 |
Why?
|
| Middle Aged | 2 | 2017 | 90450 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2009 | 9281 | 0.010 |
Why?
|
| Adult | 2 | 2014 | 81960 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 22520 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2017 | 39922 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 3707 | 0.010 |
Why?
|